Taiho Oncology Announces Multiple Presentations at the ASCO 2016 Annual Meeting

May 31, 2016

Taiho Oncology Announces Multiple Presentations at the ASCO 2016 Annual Meeting

PRINCETON, N.J., May 31, 2016 – Taiho Oncology, Inc. will present clinical data on TAS-102 at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016.

“These presentations underscore Taiho’s commitment to evaluating potential new therapeutic options for patients with cancer,” said Eric Benn, president and chief executive officer of Taiho Oncology. “We are thrilled to be a part of this year’s meeting and we look forward to opportunities to continue to research and contribute to the growing body of scientific knowledge in oncology.”

Select Presentations

Key TAS-102 data poster presentations are in Hall A during the Gastrointestinal (Noncolorectal) Cancer session Saturday, June 4 from 8:00-11:30 a.m. CT, including:    
 

Title 

 

 Lead Author

 

Poster details

 

Data Abstract

 
 

 

 
 

 

 
 

Onset of neutropenia   as an indicator of treatment response in the phase III RECOURSE trial of   TAS-102 vs placebo in patients with metastatic colorectal cancer

 
 

Atsushi Ohtsu

 
 

Abstract #3556
  Poster #253
 

 

Onset of neutropenia   as an indicator of treatment response in the randomized phase II of TAS-102   vs placebo in Japanese patients with metastatic colorectal cancer (Study   J003-10040030)

 
 

Tomohiro Nishina

 
 

Abstract #3557
  Poster #254

 
 

Efficacy and safety   results in patients with impaired renal and hepatic function in the RECOURSE   trial

 
 

Robert J. Mayer

 
 

Abstract #3547
  Poster #244

 
 

TAGS, a randomized,   double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs   placebo plus best supportive care in patients with metastatic gastric cancer   refractory to standard treatments

 
 

David H. Ilson

 
 

Abstract #TPS4141
  Poster #128a

 
 

Publication Only

 
 

Supportive   treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102   vs placebo with best supportive care in patients with metastatic colorectal   cancer

 
 

Robert J. Mayer

 
 

Abstract #e15021

 

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical aims to also offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: http://www.taiho.co.jp/english/.

About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.

For more information about Taiho Oncology, please visit: http://www.taihooncology.com.

About Otsuka Holdings Co., Ltd. (Japan)
The Otsuka Group is a global organization of 176 healthcare companies with nearly 43,000 employees (including unconsolidated subsidiaries). Otsuka Holdings Co., Ltd. is the Group’s holding company. The Group operates in 27 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and others.6

The Group’s corporate philosophy of “Otsuka-people creating new products for better health worldwide,” is supported by the corporate ethic of “JISSHO (Proof through Execution) and SOZOSEI (Creativity).” The Otsuka Group thus seeks to foster a culture and vitality appropriate to an enterprise involved with human health and to create innovative products that contribute to the health and wellness of people worldwide.

For more information, please visit the company's website at http://www.otsuka.com/en/.
###

Media Contact:
Craig Heit
GCI Health on behalf of Taiho Oncology
taihooncology@gcihealth.com
212-798-9919

Save News Release

We respect your privacy

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to